Compare CREX & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CREX | MDXH |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 41.1M |
| IPO Year | 2015 | 2021 |
| Metric | CREX | MDXH |
|---|---|---|
| Price | $3.95 | $0.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 33.2K | ★ 1.1M |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,437,000.00 | N/A |
| Revenue This Year | $81.98 | $30.78 |
| Revenue Next Year | $14.82 | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.61 | N/A |
| 52 Week Low | $2.19 | $0.51 |
| 52 Week High | $4.42 | $5.33 |
| Indicator | CREX | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 12.70 |
| Support Level | $3.52 | N/A |
| Resistance Level | $3.81 | $2.30 |
| Average True Range (ATR) | 0.26 | 0.10 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 63.11 | 17.54 |
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The company operates in one reportable segment, marketing technology solutions. It offers solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks, along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media. Geographically, the company generates maximum revenue from the United States, and the rest from Canada.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.